Rubius Therapeutics (NASDAQ:RUBY) Trading Up 6.1%

Rubius Therapeutics Inc (NASDAQ:RUBY) shares were up 6.1% on Friday . The stock traded as high as $10.87 and last traded at $10.60, approximately 298,955 shares traded hands during mid-day trading. An increase of 9% from the average daily volume of 274,227 shares. The stock had previously closed at $9.99.

Several research analysts have weighed in on RUBY shares. HC Wainwright started coverage on Rubius Therapeutics in a report on Wednesday, June 26th. They issued a “buy” rating and a $40.00 price target for the company. Zacks Investment Research upgraded Rubius Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 24th. ValuEngine upgraded Rubius Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Guggenheim started coverage on Rubius Therapeutics in a report on Thursday, May 30th. They issued a “buy” rating and a $25.00 price target for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $28.75.

The company has a fifty day simple moving average of $13.83 and a two-hundred day simple moving average of $15.32. The company has a quick ratio of 18.64, a current ratio of 17.27 and a debt-to-equity ratio of 0.21.

Rubius Therapeutics (NASDAQ:RUBY) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.04). During the same quarter in the prior year, the business posted ($3.33) earnings per share. Equities research analysts anticipate that Rubius Therapeutics Inc will post -1.93 earnings per share for the current fiscal year.

In other news, Director Robert Langer sold 7,500 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $14.94, for a total transaction of $112,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher L. Carpenter sold 47,757 shares of the business’s stock in a transaction on Wednesday, June 19th. The shares were sold at an average price of $14.02, for a total transaction of $669,553.14. The disclosure for this sale can be found here. Insiders own 58.40% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in RUBY. Janus Henderson Group PLC purchased a new stake in shares of Rubius Therapeutics during the 1st quarter valued at $14,995,000. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Rubius Therapeutics by 147.3% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,241,299 shares of the company’s stock valued at $19,526,000 after buying an additional 739,449 shares during the period. Nikko Asset Management Americas Inc. grew its stake in shares of Rubius Therapeutics by 142.3% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,254,158 shares of the company’s stock valued at $19,728,000 after buying an additional 736,490 shares during the period. Vanguard Group Inc. grew its stake in shares of Rubius Therapeutics by 29.1% during the 2nd quarter. Vanguard Group Inc. now owns 2,725,717 shares of the company’s stock valued at $42,876,000 after buying an additional 614,759 shares during the period. Finally, FMR LLC grew its stake in shares of Rubius Therapeutics by 8.9% during the 1st quarter. FMR LLC now owns 7,019,730 shares of the company’s stock valued at $127,057,000 after buying an additional 573,662 shares during the period. 95.60% of the stock is owned by institutional investors.

Rubius Therapeutics Company Profile (NASDAQ:RUBY)

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.

Further Reading: What is the Coverage Ratio?

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.